Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright boosted their price objective on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enlivex Therapeutics has a consensus rating of “Hold” and a consensus price target of $16.50.

Enlivex Therapeutics Stock Down 1.8%

Shares of NASDAQ:ENLV opened at $0.89 on Friday. Enlivex Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.10. The firm has a 50-day simple moving average of $1.02 and a 200 day simple moving average of $1.00. The company has a market cap of $211.27 million, a PE ratio of -1.62 and a beta of 1.68.

Institutional Trading of Enlivex Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd lifted its stake in shares of Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after acquiring an additional 19,132 shares during the period. Virtu Financial LLC acquired a new stake in shares of Enlivex Therapeutics in the 4th quarter worth approximately $33,000. Jane Street Group LLC lifted its stake in shares of Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after acquiring an additional 52,553 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Enlivex Therapeutics in the 3rd quarter worth approximately $57,000. Finally, Invesco Ltd. acquired a new stake in shares of Enlivex Therapeutics in the 4th quarter worth approximately $43,000. 1.02% of the stock is owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.